Adverse Drug Reactions
Conditions
Brief summary
This study aims to investigate the effect of EBV reactivation or EBV reactivation added with dexamethasone(DXM) in patients with adverse drug reactions(CDR) , through evaluating the levels on monocyte, macrophage M2/M1 and cytokines. To investigate whether expression of EBV receptors EphA2 could specifically influence on EBV activation in CDRs. We performed a prospective longitudinal study on the frequencies of Monocyte, Macrophage, M2/M1 and cytokines included IL-4,IL-13,TNF-α,IFN-γ,IFN-β, CXCL9 and CXCL10 after onset of MPE ,SJS/TEN and control groups. PBMCs collected from peripheral blood were cocultured with EBV or EBV with DXM. We next examined whether EBV or EBV with DXM could have a strong impact on the MOs, Mac, M2/M1 and cytokines and which cytokines could be crucial for the interaction between M2/M1 and EBV, by in vitro cocultures. Finally, EphA2 were detected to evaluate reactivation of EBV.
Interventions
BIOLOGICALstimulation with EB virus
stimulation with EB virus
Sponsors
First Affiliated Hospital of Kunming Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Age and Gender: The study includes male and female patients aged 18 years and older. 2. a.Erythema Multiforme (MPE) Patients: Diagnosed based on clinical presentation and medical examination findings.b.Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) Patients: Diagnosed according to the criteria set by the International Dermatology Society for SJS or TEN.c.Control Group: Healthy volunteers, without any history of chronic disease or acute infection, and not currently on any medications.
Exclusion criteria
1. Other Chronic Diseases: Patients with active heart, liver, kidney disease, or other systemic conditions. 2. Acute Infection: Patients who have had a viral or bacterial infection within the month prior to enrollment. 3. Immune Status: Patients who are immunocompromised or are receiving immunosuppressive therapy. 4. Allergy History: Patients with a known allergy to any drugs or agents used in the study. 5. Pregnancy or Lactation: Women who are currently pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes in the levels of monocytes, macrophages, M2/M1 ratio, and cytokines | 24 hours and 48 hours |
Countries
China
Outcome results
None listed